keyword
https://read.qxmd.com/read/38495394/teriparatide-as-treatment-for-severe-osteoporosis-in-lung-transplant-recipients
#21
Lisa M Raven, Louise Goodall, Jacqueline R Center, Christopher A Muir
Osteoporosis and osteopenia are common in lung transplant (LTx) recipients, with a significantly increased incidence compared to other non-lung solid organ transplant patients. Despite high fracture rates, including in patients treated with antiresorptive medications, there are limited data on the use of anabolic treatments in LTx recipients. We present clinical, biochemical and bone mineral density data for 3 patients with severe osteoporosis treated with teriparatide 20 micrograms daily for 18 months post-LTx...
March 2024: JCEM Case Rep
https://read.qxmd.com/read/38482603/cardiovascular-safety-of-romosozumab-vs-pth-analogs-for-osteoporosis-treatment-a-propensity-score-matched-cohort-study
#22
JOURNAL ARTICLE
Joshua Stokar, Auryan Szalat
CONTEXT: Romosozumab, a monoclonal sclerostin antibody, is a recently approved highly potent anti-osteoporotic agent with osteoanabolic properties. Clinical use of Romosozumab is hindered by the fear of adverse cardiovascular (CV) events raised following the pivotal ARCH-trial. OBJECTIVE: To assess real-world CV safety of romosozumab vs. alternative osteoanabolic therapies used for treatment of severe osteoporosis. DESIGN: Data was obtained from TriNetX, a global federated health research network including real-time electronic medical records from 113 healthcare organizations with a total of 136,460,930 patients across 16 countries at time of analysis...
March 14, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38479212/report-of-a-collaborative-study-to-establish-the-first-indian-pharmacopoeia-reference-standard-for-teriparatide
#23
JOURNAL ARTICLE
Gaurav Pratap Singh Jadaun, M Kalaivani, Mukesh Kumar, Gyanendra Nath Singh, Rajeev Singh Raghuvanshi, Parveen Jain
A collaborative study was conducted to establish the first Indian Pharmacopoeia Reference Standard (IPRS) for teriparatide to be used in quality control testing of marketed products in compliance with the Indian Pharmacopoeia (IP) monograph. The study objective was to evaluate the candidate standard in terms of the WHO International Standard (IS) to assign its content in mg per vial terms. This study involved four laboratories from India and the candidate standard was calibrated against the WHO IS by each participant laboratory using high-performance liquid chromatography (HPLC) assay method per IP monograph...
March 12, 2024: Biologicals: Journal of the International Association of Biological Standardization
https://read.qxmd.com/read/38477812/osteoporosis-presenting-during-pregnancy-and-lactation-wait-and-reassess
#24
JOURNAL ARTICLE
Christopher S Kovacs
Two months after her first pregnancy, a 35-year-old exclusively breastfeeding woman bent to move her baby in the car seat and experienced sudden, severe pain from five spontaneous vertebral compression fractures. Genomic screen was negative but she had mild ankylosing spondylitis previously well controlled on Etanercept. She was vegetarian with a high phytate intake. A lactation consultant had advised her to pump and discard milk between feeds, such that she believed she produced twice as much milk as her baby ingested...
March 4, 2024: Journal of Bone and Mineral Research
https://read.qxmd.com/read/38472351/current-and-developing-pharmacologic-agents-for-improving-skeletal-health-in-adults-with-osteogenesis-imperfecta
#25
REVIEW
Winnie Liu, Lindsey Nicol, Eric Orwoll
Osteogenesis imperfecta (OI) is a genetic disorder characterized by increased bone fragility largely caused by defects in structure, synthesis, or post-translational processing of type I collagen. Drugs currently used to improve skeletal health in OI were initially developed to treat osteoporosis and clinical trials are ongoing to study their effectiveness in OI adults. Additionally, novel bone-protective agents are in preclinical studies and various phases of OI clinical trials. This review summarizes current knowledge on available pharmacologic agents and current drug trials involving OI participants...
March 12, 2024: Calcified Tissue International
https://read.qxmd.com/read/38454520/teriparatide-and-clodronate-combination-as-a-potential-treatment-for-complex-regional-pain-syndrome-type-i-in-delayed-consolidation-after-foot-surgery-a-case-report-and-review-of-the%C3%A2-literature
#26
JOURNAL ARTICLE
F Di Sacco, D Antognetti, G Ciapini, M Nicastro, M Scaglione, V Bottai
BACKGROUND: Complex regional pain syndrome type I is a pathological condition characterized by an exaggerated response of tissues to low or moderate pain stimuli. The exact pathogenesis and optimal medical treatment for complex regional pain syndrome type I are still not fully understood, although bisphosphonates have shown positive effects in reducing pain. Foot surgery can be complicated by the development of complex regional pain syndrome type I, leading to functional decline and difficulties in weight-bearing...
March 8, 2024: Journal of Medical Case Reports
https://read.qxmd.com/read/38453825/exploring-epigenetic-strategies-for-the-treatment-of-osteoporosis
#27
REVIEW
Sun-Ju Yi, Jaeho Lim, Kyunghwan Kim
The worldwide trend toward an aging population has resulted in a higher incidence of chronic conditions, such as osteoporosis. Osteoporosis, a prevalent skeletal disorder characterized by decreased bone mass and increased fracture risk, encompasses primary and secondary forms, each with distinct etiologies. Mechanistically, osteoporosis involves an imbalance between bone resorption by osteoclasts and bone formation by osteoblasts. Current pharmacological interventions for osteoporosis, such as bisphosphonates, denosumab, and teriparatide, aim to modulate bone turnover and preserve bone density...
March 8, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38443685/medication-related-osteonecrosis-of-the-jaw-evolving-research-for-multimodality-medical-management
#28
REVIEW
Ali Abdolrahmani, Joel B Epstein, Firoozeh Samim
PURPOSE: Medication-related osteonecrosis of the jaw (MRONJ) is a debilitating side effect of antiresorptive and antiangiogenic agents that can lead to progressive bone destruction in the maxillofacial region. Dental surgery, including tooth extractions, commonly trigger the onset of MRONJ. While guidelines suggest avoiding extraction when possible, complete avoidance is not always feasible, as necrosis can develop from dental and periodontal disease without dental procedures. The goal of this article is to provide an update review of current preventive and therapeutic approaches for MRONJ...
March 5, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38420739/treatment-of-osteoporosis-after-hip-fracture-survey-of-the-korean-hip-society
#29
JOURNAL ARTICLE
Jung-Wee Park, Je-Hyun Yoo, Young-Kyun Lee, Jong-Seok Park, Ye-Yeon Won
PURPOSE: To assess current practice in the treatment of osteoporosis in patients who underwent treatment for hip fracture in South Korea. MATERIALS AND METHODS: A survey of 97 members of the Korean Hip Society, orthopedic hip surgeons who administer treatment for hip fractures in South Korea, was conducted. The survey was conducted for assessment of demographic data and perceptions regarding the management of osteoporosis in patients who have undergone treatment for hip fracture...
March 1, 2024: Hip & Pelvis
https://read.qxmd.com/read/38389884/design-synthesis-and-biological-evaluation-of-novel-pyrimidine-derivatives-as-bone-anabolic-agents-promoting-osteogenesis-via-the-bmp2-smad1-signaling-pathway
#30
JOURNAL ARTICLE
Sumit K Rastogi, Sonu Khanka, Santosh Kumar, Amardeep Lakra, Rajat Rathur, Kriti Sharma, Amol Chhatrapati Bisen, Rabi Sankar Bhatta, Ravindra Kumar, Divya Singh, Arun K Sinha
Anti-resorptive inhibitors such as bisphosphonates are widely used but they have limited efficacy and serious side effects. Though subcutaneous injection of teriparatide [PTH (1-34)] is an effective anabolic therapy, long-term repeated subcutaneous administration is not recommended. Henceforth, orally bio-available small-molecule-based novel therapeutics are unmet medical needs to improve the treatment. In this study, we designed, synthesized, and carried out a biological evaluation of 31 pyrimidine derivatives as potent bone anabolic agents...
February 21, 2024: RSC medicinal chemistry
https://read.qxmd.com/read/38376326/primary-hyperparathyroidism-and-sarcoma-a-case-report-and-literature-review
#31
JOURNAL ARTICLE
Burak Alper Zengin, Adile Begüm Bahçecioğlu, Murat Faik Erdoğan
The relationship between primary hyperparathyroidism (PHPT) and bone sarcoma is debatable, especially after wider use of teriparatide treatment, concerns have intensified on the issue. Extensive search in English literature revealed 10 cases reported having PHPT and sarcomas. Besides, three cases of bone sarcoma occurring after teriparatide treatment had been reported. Hereby, we report a 51-year-old woman with a prolonged history of PHPT. She was diagnosed with chondrosarcoma 9 years after refusal and lack of treatment for PHPT...
October 1, 2023: Journal of Cancer Research and Therapeutics
https://read.qxmd.com/read/38374820/teriparatide-and-etelcalcetide-improve-bone-fibrosis-and-fat-parameters-in-chronic-kidney-disease-model-rats
#32
JOURNAL ARTICLE
Shun Igarashi, Yuji Kasukawa, Koji Nozaka, Hiroyuki Tsuchie, Kazunobu Abe, Hikaru Saito, Ryo Shoji, Fumihito Kasama, Shuntaro Harata, Kento Okamoto, Keita Oya, Naohisa Miyakoshi
OBJECTIVES: Chronic kidney disease (CKD) complicated by secondary hyperparathyroidism (SHPT) is associated with an increased risk of fragility fractures. Etelcalcetide (EC) is a treatment for SHPT that reduces serum parathyroid hormone (PTH) levels. However, the effects of combined treatment with osteoporosis drugs such as teriparatide (TPTD) remain unclear. This study investigates the combined effects of EC and TPTD on bone in CKD model rats. METHODS: The CKD model was established in 8-week-old male Wistar rats by feeding them a 0...
December 2023: Osteoporosis and Sarcopenia
https://read.qxmd.com/read/38360197/abaloparatide-is-more-potent-than-teriparatide-in-restoring-bone-mass-and-strength-in-type-1-diabetic-male-mice
#33
JOURNAL ARTICLE
Silvia Marino, Serra Ucer Ozgurel, Kevin McAndrews, Meloney Cregor, Alma Villaseñor, Maricuz Mamani-Huanca, Coral Barbas, Arancha Gortazar, Amy Y Sato, Teresita Bellido
This study investigated the efficacy of the two FDA-approved bone anabolic ligands of the parathyroid hormone receptor 1 (PTH1R), teriparatide or human parathyroid hormone 1-34 (PTH) and abaloparatide (ABL), to restoring skeletal health using a preclinical murine model of streptozotocin-induced T1-DM. Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice...
February 13, 2024: Bone
https://read.qxmd.com/read/38342711/anti-osteoporotic-drug-efficacy-for-periprosthetic-bone-loss-after-total-hip-arthroplasty-a-systematic-review-and-network-meta-analysis
#34
JOURNAL ARTICLE
Masaki Hatano, Yasuhiko Koizumi, Norio Yamamoto, Kota Miyoshi, Kensuke Kawabata, Takeyuki Tanaka, Sakae Tanaka, Akihiro Shiroshita, Yuki Kataoka
BACKGROUND: Periprosthetic bone loss following total hip arthroplasty (THA) threatens prosthesis stability. This systematic review and network meta-analysis aimed to compare the efficacy of anti-osteoporotic drugs for measures of hip function according to functional outcomes, periprosthetic femoral bone mineral density loss in each Gruen zone, and revision surgery after THA. METHODS: The systematic search of six literature databases was conducted in December 2021 in accordance with PRISMA guidelines...
February 10, 2024: Journal of Orthopaedic Science: Official Journal of the Japanese Orthopaedic Association
https://read.qxmd.com/read/38323990/does-teriparatide-improve-outcomes-in-osteoporotic-patients-undergoing-adult-spinal-deformity-surgery-commentary-on-an-article-by-sarthak-mohanty-bs-et-al-impact-of-teriparatide-on-complications-and-patient-reported-outcomes-for-patients-undergoing-long-spinal
#35
JOURNAL ARTICLE
https://read.qxmd.com/read/38313307/denosumab-teriparatide-and-bisphosphonates-for-glucocorticoid-induced-osteoporosis-a-bayesian-network-meta-analysis
#36
Liang Dong, Lianghai Jiang, Zhengwei Xu, Xiaobo Zhang
Background: Several medications have been used for glucocorticoids-induced osteoporosis (GIO). However, the best therapeutic option for GIO is still controversial. A Bayesian network meta-analysis was conducted to compare the efficacy and safety of denosumab, teriparatide and bisphosphonates for patients with GIO. Methods: Relevant randomized controlled trials published in PubMed, Embase, Cochrane Library and ClinicalTrials.gov up to August 2023 were searched. The following efficiency and safety outcomes were extracted for comparison: bone mineral density (BMD) percentage changes in lumbar spine, femur neck and total hip, and incidences of adverse events (AEs), serious adverse events (SAEs), vertebrae and non-vertebrae fracture...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38310278/analyzing-the-factors-associated-with-efficacy-among-teriparatide-treatment-in-postmenopausal-women-with-osteoporosis
#37
JOURNAL ARTICLE
Meng Kong, Changtong Gao, Xiaona Luan, Cuiying Fan, Meng Hao, Canghai Jin, Jiangning Zhao, Hongyan Li, Jindong Zhao, Jian Luan, Yong Lin, Qiang Li
BACKGROUND: Teriparatide (TPTD) is a widely used anabolic agent for the treatment of osteoporosis. Several factors have been identified to be related to bone mineral density (BMD) increase in anti-osteoporosis treatment with other agents; however, there has been no systematic analysis to summarize the associated determinants of BMD reaction to daily teriparatide treatment. METHODS: In this retrospective study, we performed a comprehensive investigation involving not only clinical data but also several relevant lifestyle factors to be examined for their potential contribution to BMD response...
February 3, 2024: BMC Musculoskeletal Disorders
https://read.qxmd.com/read/38289413/comparison-of-the-cost-effectiveness-of-sequential-treatment-with-abaloparatide-in-us-men-and-women-at-very-high-risk-of-fractures
#38
JOURNAL ARTICLE
Mickael Hiligsmann, Stuart L Silverman, Andrea J Singer, Leny Pearman, Yamei Wang, John Caminis, Jean-Yves Reginster
BACKGROUND: Osteoporotic-related fractures represent an increasing burden to patients, health care systems and society. AIMS: This study estimated cost-effectiveness of sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) compared to relevant alternative strategies in US men and women aged 50 to 80 years at very high fracture risk (bone mineral density T-score ≤  - 2.5 and a recent fracture). METHODS: A lifetime Markov-based microsimulation model was used to estimate healthcare costs and quality-adjusted life years (QALYs)...
January 30, 2024: Aging Clinical and Experimental Research
https://read.qxmd.com/read/38284095/mechanistic-modeling-of-size-exclusion-chromatography-assisted-in-vitro-refolding-of-the-recombinant-biosimilar-teriparatide-pth-34
#39
JOURNAL ARTICLE
Santosh Ughade, Sunil Rana, Mohd Nadeem, Rupali Kumthekar, Sanjay Mahajani, Rahul Bhambure
In vitro protein refolding is one of the critical unit operations in manufacturing recombinant peptides expressed using Escherichia coli as host cells. This study is focused on designing size exclusion chromatography-assisted in vitro refolding process for biosimilar recombinant parathyroid hormone. Inclusion bodies (IBs) of recombinant parathyroid hormone were solubilized at higher pH, and in vitro refolding was performed using size exclusion chromatography. In the first part of the investigation, DoE-based empirical optimization was performed to achieve a higher refolding yield for a biosimilar recombinant parathyroid hormone...
January 23, 2024: ACS Omega
https://read.qxmd.com/read/38283430/osteoporotic-burst-fracture-in-a-young-male-adult-as-first-presentation-of-a-rare-pls3-mutation-a-case-report
#40
Stefania Nikolaou, Ioannis Chatzikomninos, Ioannis Palavos, Paraskevi Langourani-Kosteletou, Kristallia Vitoula
Low-impact spinal fractures in young patients are rare and should raise suspicion of an underlying condition, as these injuries are typically the result of high-energy trauma. We describe a case of a young male patient who sustained a burst fracture of the first lumbar vertebra (L1) following low-energy trauma. The patient underwent percutaneous posterior spinal instrumentation, yet the poor bone quality detected intraoperatively prompted further diagnostic evaluation. Subsequently, low bone mineral density (BMD) was detected, and a rare plastine-3 ( PLS3 ) gene mutation was revealed in the genetic analysis...
December 2023: Curēus
keyword
keyword
112
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.